Treatment
Fdg clinical trials
We’re tracking 148 recruiting studies that include Fdg, each written for real people, not researchers, below.
Recruiting studies
- NCT06224309Recruiting
Testing a new imaging tracer for certain blood cancers
This trial tests a new PET/CT imaging tracer called [18F]BL40 to see if it can help spot certain types of blood cancers. It may help doctors better understand and monitor these diseases.
Vancouver, British ColumbiaAges 19–100 - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT06103838RecruitingPhase 2
Fluciclovine PET/CT scan for multiple myeloma
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
Bethesda, MarylandAges 18–120 - NCT06083103Recruiting
PET/MRI for advanced cervical cancer
This trial uses a combined PET and MRI scan to see if it can better identify the spread of cervical cancer before treatment. It may help guide more personalized care.
StrasbourgAges 18 years+ - NCT06102057RecruitingPhase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
DresdenAges 18 years+ - NCT06050694RecruitingPhase 2
Testing glofitamab plus chemo for untreated DLBCL
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
Toronto, OntarioAges 18 years+ - NCT06014515RecruitingEarly Phase 1
Single injection PET scan to study body metabolism
This study uses a single injection and a special type of PET scan to look at how your body's tissues use fuel (metabolism). It helps researchers learn more about normal and disease-related changes in the heart, liver, and other organs.
Sacramento, CaliforniaAges 18 years+ - NCT05828069RecruitingPhase 2
Tovorafenib for young people with worsening Langerhans cell histiocytosis
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Birmingham, AlabamaAges 6 months–22 years - NCT05806697Recruiting
Study of brain scan clues in people worried about memory
This extension study looks for predictors—measurable clues—linked to memory changes in older adults who feel their memory is worsening. You may be asked to have an amyloid PET scan, which can help researchers understand what might be driving memory concerns.
Paris, Île-de-France RegionAges 70–95 - NCT05647564Recruiting
PET/CT scan to study why prostate cancer resists treatment
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
Madison, WisconsinAges 18 years+ - NCT05641753RecruitingPhase 4
LDL-lowering study for adults with type 1 diabetes
This study looks at cholesterol lowering in adults with type 1 diabetes and whether it reduces “residual risk,” meaning risk that may remain even with current care. You may be asked to take cholesterol-focused treatment and complete blood tests to track LDL (“bad cholesterol”).
New York, New YorkAges 18–89 - NCT05436093Recruiting
PET scan using a tumor-targeting probe in solid tumors
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
Beijing, Beijing MunicipalityAges 18–75 - NCT05321316Recruiting
PET scan test for bladder cancer using a targeted tracer
This trial studies a special PET/CT scan tracer that is designed to bind to a protein (Nectin-4) found in some bladder cancers. It aims to help doctors see and stage tumors more clearly, which could improve diagnosis and treatment planning.
Beijing, Beijing MunicipalityAges 18–75 - NCT05308888RecruitingPhase 2
PET scan study of heart inflammation after aortic valve replacement
This Phase 2 trial uses a PET scan to study how local inflammation inside the heart affects the heart’s electrical wiring after a minimally invasive aortic valve procedure. The results may help doctors better predict or prevent rhythm and conduction problems after treatment.
BrestAges 18 years+ - NCT05191940Recruiting
Radiation for advanced pancreatic cancer you can’t remove by surgery
This trial studies how well radiation therapy works for pancreatic cancer that is locally advanced (near important blood vessels) and cannot be removed with surgery. It may help shrink or control the cancer when surgery isn’t an option.
Wiener Neustadt, Lower AustriaAges 18 years+ - NCT05160480Enrolling by invitation
Total-body PET scan using FDA-approved tracers for prostate or NET cancer
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Sacramento, CaliforniaAges 18 years+ - NCT05137119RecruitingPhase 4
Adaptive study of treatments for staph bloodstream infection
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
Houston, TexasAges Any age - NCT05108857Enrolling by invitation
PET scan study for early active systemic sclerosis
This trial uses PET/CT scans with special tracers to look at inflammation and activity in systemic sclerosis (scleroderma) soon after symptoms begin. It may help researchers understand what’s driving active disease and where it shows up in the body.
TurkuAges 18 years+ - NCT05015881Enrolling by invitationPhase 2/Phase 3
Brain and heart scans in alcohol use disorder
This study uses special brain and heart scans to see how sugar (glucose) is used in people with alcohol use disorder compared with people without it. It may help researchers understand the brain–heart connection in alcohol use disorder.
Philadelphia, PennsylvaniaAges 21–65 - NCT04901884Recruiting
PET/MR scans before and after radiation for heart-lung effects
This study uses special PET/MR imaging before and after radiation treatment to better understand how radiation may affect the heart and lungs. It may help researchers find ways to predict and monitor these side effects using imaging and blood tests.
Toronto, OntarioAges 18 years+ - NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+ - NCT04612075Recruiting
PET-MR scan study for head and neck squamous cancer
This study uses a combined PET/MR scan to better look at head and neck squamous cell cancer before or during treatment. It may help doctors see where the cancer is and how far it has spread, to support planning for curative radiation treatment.
TromsøAges 18 years+ - NCT04362644RecruitingPhase 1
Imaging agent study for idiopathic pulmonary fibrosis lung scarring
This Phase 1 study tests a specialized imaging agent that can help show differences (heterogeneity) in lung scarring in idiopathic pulmonary fibrosis (IPF). It’s mainly about safety and whether the imaging works for people with certain genetic and lung-function features.
Birmingham, AlabamaAges 40–85
Common questions
- Are there clinical trials studying Fdg?
- Yes. Clin2 currently lists 148 recruiting studies that include Fdg, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Fdg trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Fdg an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Fdg or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.